Seres Therapeutics, Inc. to Post FY2017 Earnings of ($2.18) Per Share, Oppenheimer Holdings Forecasts (MCRB)

Seres Therapeutics, Inc. (NASDAQ:MCRB) – Stock analysts at Oppenheimer Holdings lifted their FY2017 earnings estimates for Seres Therapeutics in a research report issued to clients and investors on Wednesday. Oppenheimer Holdings analyst M. Breidenbach now anticipates that the biotechnology company will earn ($2.18) per share for the year, up from their prior estimate of ($2.26). Oppenheimer Holdings currently has a “Outperform” rating and a $19.00 target price on the stock. Oppenheimer Holdings also issued estimates for Seres Therapeutics’ Q4 2017 earnings at ($0.68) EPS, Q1 2018 earnings at ($0.64) EPS, Q2 2018 earnings at ($0.65) EPS, Q3 2018 earnings at ($0.67) EPS, Q4 2018 earnings at ($0.69) EPS, FY2018 earnings at ($2.65) EPS, Q1 2019 earnings at ($0.73) EPS, Q2 2019 earnings at ($0.24) EPS, Q3 2019 earnings at ($0.29) EPS, FY2019 earnings at ($1.97) EPS, FY2020 earnings at ($1.40) EPS and FY2021 earnings at ($1.81) EPS.

Seres Therapeutics (NASDAQ:MCRB) last posted its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.17) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.39) by $0.22. The company had revenue of $23.00 million for the quarter, compared to analyst estimates of $17.29 million. Seres Therapeutics had a negative net margin of 267.15% and a negative return on equity of 82.11%. The business’s revenue for the quarter was up 76.9% compared to the same quarter last year. During the same period last year, the business posted ($0.46) earnings per share.

ILLEGAL ACTIVITY NOTICE: This story was originally published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The legal version of this story can be viewed at https://sportsperspectives.com/2017/11/14/seres-therapeutics-inc-to-post-fy2017-earnings-of-2-18-per-share-oppenheimer-holdings-forecasts-mcrb.html.

Other equities research analysts have also issued reports about the stock. BidaskClub upgraded shares of Seres Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, July 25th. Seaport Global Securities reiterated a “buy” rating and issued a $20.00 target price on shares of Seres Therapeutics in a report on Friday, October 6th. Cowen and Company reiterated a “buy” rating on shares of Seres Therapeutics in a report on Monday, October 2nd. HC Wainwright reiterated a “buy” rating and issued a $19.00 target price (up from $15.00) on shares of Seres Therapeutics in a report on Friday, August 4th. Finally, Canaccord Genuity set a $20.00 target price on shares of Seres Therapeutics and gave the stock a “buy” rating in a report on Thursday, August 3rd. One analyst has rated the stock with a sell rating, two have issued a hold rating and nine have issued a buy rating to the company’s stock. Seres Therapeutics presently has an average rating of “Buy” and an average price target of $18.00.

Shares of Seres Therapeutics (MCRB) opened at $9.66 on Monday. The company has a quick ratio of 6.53, a current ratio of 6.53 and a debt-to-equity ratio of 0.11. Seres Therapeutics has a twelve month low of $8.85 and a twelve month high of $17.42.

Several hedge funds have recently modified their holdings of the company. Parametric Portfolio Associates LLC increased its position in shares of Seres Therapeutics by 1.3% during the first quarter. Parametric Portfolio Associates LLC now owns 21,335 shares of the biotechnology company’s stock worth $240,000 after acquiring an additional 279 shares in the last quarter. California State Teachers Retirement System increased its position in shares of Seres Therapeutics by 1.1% during the second quarter. California State Teachers Retirement System now owns 36,280 shares of the biotechnology company’s stock worth $410,000 after acquiring an additional 400 shares in the last quarter. Teachers Advisors LLC increased its position in shares of Seres Therapeutics by 1.2% during the second quarter. Teachers Advisors LLC now owns 38,758 shares of the biotechnology company’s stock worth $438,000 after acquiring an additional 450 shares in the last quarter. Schwab Charles Investment Management Inc. increased its position in shares of Seres Therapeutics by 0.5% during the second quarter. Schwab Charles Investment Management Inc. now owns 91,543 shares of the biotechnology company’s stock worth $1,035,000 after acquiring an additional 494 shares in the last quarter. Finally, American International Group Inc. increased its position in shares of Seres Therapeutics by 7.1% during the first quarter. American International Group Inc. now owns 10,977 shares of the biotechnology company’s stock worth $124,000 after acquiring an additional 727 shares in the last quarter. 74.77% of the stock is owned by institutional investors.

About Seres Therapeutics

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

Earnings History and Estimates for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply